Abstract
Chronic spontaneous urticaria is an itching skin disease characterised by wheals, angioedema, or both present for more than six weeks. Omalizumab is a humanized anti-IgE monoclonal antibody recently approved for treatment of chronic urticaria. Several randomised controlled trials have investigated the safety, tolerability, and efficacy of omalizumab for chronic urticaria. The safety of omalizumab in pregnancy is not known. We describe a female patient with chronic spontaneous urticaria who was treated with omalizumab continuously through two consecutive pregnancies with convincing results and no apparent toxicity.
| Original language | English |
|---|---|
| Journal | Case reports in medicine |
| Volume | 2015 |
| Pages (from-to) | 368053 |
| ISSN | 1687-9627 |
| DOIs | |
| Publication status | Published - 2015 |